FindTrial
Sign In

A Randomized Controlled Study on the Application of Preoperative Oral Supplementation with Medium-Chain Triglycerides Based on the Concept of Enhanced Recovery After Surgery and Its Impact on the Perioperative Period of Colorectal Cancer Patients

A Randomized Controlled Study on the Application of Preoperative Oral Supplementation with Medium-Chain Triglycerides Based on the Concept of Enhanced Recovery After Surgery and Its Impact on the Perioperative Period of Colorectal Cancer Patientse cancer of colon

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082795
Enrollment
Unknown
Registered
2024-04-08
Start date
2024-05-18
Completion date
Unknown
Last updated
2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

control group:A 12.5% maltodextrin (CHO) solution was administered at a volume of 800ml 10 hours prior to surgery, followed by an additional =400ml given 2 hours before the surgery.
experimental group:A combination solution of medium chain triglyceride (MCT) and carbohydrate (CHO) was administered at a volume of 800ml 10 hours before surgery, followed by an additional =400ml give

Sponsors

Nutrition Department of the first medical center of PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients with histopathologically confirmed colorectal cancer (2) Patients undergoing elective colorectal cancer surgery (3) Aged 18-80 years; no gender restriction (4) Body Mass Index (BMI) between 18.5 and 28 kg/m² (5) American Society of Anesthesiologists (ASA) classification of I or II (6) No severe malnutrition, and no severe respiratory, cardiovascular, or other underlying diseases (7) No previous history of gastrointestinal surgery (8) Patients agree to receive Enhanced Recovery After Surgery (ERAS) management and agree with the relevant treatment plan (9) Voluntarily participate in this clinical study and sign the informed consent form (10) Agree to maintain complete preoperative, intraoperative, and postoperative clinical data and follow-up records

Exclusion criteria

Exclusion criteria: (1) History of early gastric surgery or known medications affecting gastric emptying (2) Patients with gastric emptying disorders, preoperative or postoperative nasogastric tube insertion (3) Patients with intestinal obstruction (4) Severe underlying comorbidities involving the heart, lungs, liver, or kidneys before surgery (5) Preoperative infection or severe bleeding (6) Preoperative autoimmune diseases or hematological disorders (7) Patients with other gastrointestinal tumors (8) Emergency surgery patients (9) Termination of cooperation due to personal or family reasons

Design outcomes

Primary

MeasureTime frame
Fasting insulin;Fasting blood glucose;HOMA-IR;White blood cell count level;Interleukin 6;C-reactive protein;Tumor necrosis factor;Total albumin;albumin;prealbumin;—

Secondary

MeasureTime frame
Intestinal flora;Antrum cross-sectional area;Intraoperative fluid usage; Blood biochemical test;Length of stay;First time out of bed activity;—

Countries

China

Contacts

Public ContactLiu Yinghua

Chinese PLA General Hospital

liuyinghua77@163.com+86 10 6693 9619

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026